Market Highlights
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the growing number of patients affected with lymphoma and multiple myeloma is also fueling the growth of the global retinal vein occlusion market.
According to the Centers for Disease Control and Prevention, in 2014, around 47,135 people were diagnosed with leukemia and out of which 23,564 people died from the disease. According to the American Cancer Society, around 4% of all cancers in the United States is lymphoma, additionally, it is estimated that in 2018, about 74,680 people including both adults and children will be diagnosed with lymphoma and around 19,910 people will die from this. According to the American Cancer Society, the risk of acquiring multiple myeloma in the United States is 1 in 143 that is 0.7%, additionally, it is estimated that in 2018, around 30,770 new cases are likely to be diagnosed and the estimated death toll would be around 12,770.
The global retinal vein occlusion treatment market is expected to grow at a CAGR of 11.2% during the forecast period 2017-2023.
Taste the market data and market information presented through more than 150 market data tables and figures spread over 206 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “retinal vein occlusion market research report–Global forecast till 2023.”
Major Players in the Retinal Vein Occlusion Market
Some of the key players in this market are Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers, GlaxoSmithKline Plc, IRIDEX Corporation, Novartis, Quantel Medical Inc, Topcon Medical Systems, Inc., ZEISS, Lumenis, Sanofi Aventis, Valeant Pharmaceuticals, Alimera Sciences, Fovea Pharmaceuticals SA, Icon Biosciences, Suzuken Co.Ltd, Genentech, Inc., Ranbaxy Pharmaceuticals, Johnson & Johnson Services, Inc, Teva Pharmaceutical, Pfizer Inc., Astrazeneca, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB and others.
The global retinal vein occlusion market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas dominate the global retinal vein occlusion market owing to the increasing prevalence of eye diseases. Additionally, high healthcare spending, well-developed technology, and increasing geriatric population will fuel the growth of the market.
The Americas market for retinal vein occlusion is divided into North America and South America. North America holds the major share in the market whereas, South America is showing the fastest growth owing to the presence of a huge opportunity for the development of the market in the region.
The Europe retinal vein occlusion market comprises of Eastern Europe and Western Europe. Western Europe comprises of countries such as Germany, the U.K, France, Italy, and Spain. Europe accounts for the second largest market for the global retinal vein occlusion owing to increasing support from the government, the presence of huge geriatric population, and high healthcare spending. Also, many European countries are trying to encourage the manufacturers for research & development for the introduction of advanced devices. In addition to this, increasing awareness and development in the healthcare infrastructure has provided a push to the growth of the market.
Asia Pacific is the fastest growing market for the global retinal vascular or vein occlusion. Presence of huge patient population, rapid development in technology and presence of a huge opportunity for the development of the market drives the growth of Asia Pacific retinal vascular or vein occlusion market. Also, the government of this region is looking forward to avail better treatment options from developed nations in order to improve the quality of life of their citizens. Additionally, growing geriatric population is also fueling the growth of the market in this region.
On the other hand, the Middle East & Africa holds the least share but will be a fastest growing region in the forecast period. However, due to the presence of poor and slow developing countries, especially, in the African region, it may hold least market share.
Segmentation
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis of the condition, it is segmented into non-ischemic and ischemic. Based on the diagnosis, it is segmented into optical coherence tomography (OCT), fundoscopic examination, fluorescein angiography, and others. On the basis of treatment, it is segmented into antivascular endothelial growth factor, corticosteroid drugs, laser retinal photocoagulation, and others. On the basis of the end users, it is segmented into hospitals and clinics, research & academics centers, and others.
Access Complete Report @ https://www.marketresearchfuture.com/reports/retinal-vein-occlusion-market-5377
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Email: [email protected]
This report on the Global Retinal Vein Occlusion Market provides a global 360-degree perspective of the industry while taking into consideration historical data as well as providing accurate estimations of the future scope of the market.
This make it easier for the stakeholders of the report to utilize this information and incorporate changes in their business policies and be well informed about the market dynamics.
It also provides an insight into the competitive landscape of the market highlighting key competitors, major manufacturers dominating the Retinal Vein Occlusion Market, while also providing an analysis of the market share and revenue generation figures.Ask for report free sample with complete TOC and list of tables/figures @ https://www.datalibraryresearch.com/sample-request/retinal-vein-occlusion-market-2221Global Retinal Vein Occlusion Market Competitive Analysis:GlaxoSmithKline plc,Sanofi,Johnson & Johnson Services, Inc.,AstraZeneca,Bausch & Lomb Incorporated,Bristol-Myers Squibb Company,Bayer AG,Sun Pharmaceutical Industries Ltd.,Regeneron, Drivers & ConstraintsThe report largely stresses on the importance of market dynamics in understanding the Retinal Vein Occlusion Market industry.
It also includes the impact that governmental policies in different regions has on the market growthFor More Enquiry and Discount related quarries: https://www.datalibraryresearch.com/enquiry/retinal-vein-occlusion-market-2221Regional DescriptionThe report provides an in-depth detailed analysis of the regions that the Retinal Vein Occlusion Market spans across.
Sales revenues, population, production rates, consumption rates, existence of key manufacturers in regions are all points that have been touched base upon in the report providing an overall comparison of each of the regions covered in the report.
Additionally, the report also calls out regions that have showed maximum growth in the past as well as regions that emerged as leaders of the market in historic years.
Retinal Vein Occlusion Market: IntroductionAccording to the report, the global retinal vein occlusion market was valued at US$ 15.6 Bn in 2020 and is projected to expand at a CAGR of 7.3% from 2021 to 2031.
Retinal vein occlusion is the blockage of the retinal vein due to blood clot.
A blood clot causes a blockage in the vein, which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person.
Rise in prevalence of eye diseases globally, increase in the geriatric population, surge in awareness about eye disorders, improved healthcare infrastructure, technological advancements, and upcoming novel treatments are the major drivers of the global retinal vein occlusion market.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=60489North America held major share of the global retinal vein occlusion market in 2020 due to improved healthcare infrastructure, rise in prevalence of eye diseases, advanced technology, and increase in the geriatric population.
The central retinal vein occlusion segment dominated the global retinal vein occlusion market in 2020, and the trend is projected to continue during the forecast period.Request COVID Analysis on Retinal Vein Occlusion Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=60489 Anti-VEGF Drugs Held Major Share of Global MarketBased on treatment type, the global retinal vein occlusion market has been classified into anti-VEGF drugs, corticosteroid drugs, pan-retinal photocoagulation therapy, and laser therapy.
India and China are likely to be lucrative markets for retinal vein occlusion treatment during the forecast period.Buy Retinal Vein Occlusion Market Report– https://www.transparencymarketresearch.com/checkout.php?rep_id=60489=SGrowth Strategies of Key PlayersKey players operating in the global retinal vein occlusion market are Alimera Sciences, Allergan (AbbVie, Inc.), Annexin Pharmaceuticals AB (publ), Bayer AG, Carl Zeiss AG, F. Hoffmann-La Roche Ltd., Iridex Corporation, Lumenis, Nidek Co., Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., and Topcon Corporation.
Herbal Treatment for Retinal Vein Occlusion read the Symptoms and Causes.
Retinal Vein Occlusion is a blockage of the small veins that carry blood away from the retina.
It's a common retina disorder and a major cause of vision loss.
Herbal Treatment for Retinal Vein Occlusion read the Symptoms and Causes.
Natural Remedies for Retinal Vein Occlusion or Supplement best option for lessen the symptoms.
